216 related articles for article (PubMed ID: 26284582)
21. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia.
Veuger MJ; Honders MW; Landegent JE; Willemze R; Barge RM
Blood; 2000 Aug; 96(4):1517-24. PubMed ID: 10942400
[TBL] [Abstract][Full Text] [Related]
22. Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide.
Turk S; Turk C; Akbar MW; Kucukkaraduman B; Isbilen M; Demirkol Canli S; Malkan UY; Okay M; Ucar G; Sayinalp N; Haznedaroglu IC; Gure AO
PLoS One; 2020; 15(11):e0242497. PubMed ID: 33237942
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.
Brendel C; Teichler S; Millahn A; Stiewe T; Krause M; Stabla K; Ross P; Huynh M; Illmer T; Mernberger M; Barckhausen C; Neubauer A
PLoS One; 2015; 10(4):e0123181. PubMed ID: 25901794
[TBL] [Abstract][Full Text] [Related]
24. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
[TBL] [Abstract][Full Text] [Related]
25. Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms.
Tatsumi N; Hojo N; Sakamoto H; Inaba R; Moriguchi N; Matsuno K; Fukuda M; Matsumura A; Hayashi S; Morimoto S; Nakata J; Fujiki F; Nishida S; Nakajima H; Tsuboi A; Oka Y; Hosen N; Sugiyama H; Oji Y
PLoS One; 2015; 10(6):e0130578. PubMed ID: 26090994
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
Minderman H; Zhou Y; O'Loughlin KL; Baer MR
Cancer Chemother Pharmacol; 2007 Jul; 60(2):245-55. PubMed ID: 17096161
[TBL] [Abstract][Full Text] [Related]
27. c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia.
Lagadinou ED; Ziros PG; Tsopra OA; Dimas K; Kokkinou D; Thanopoulou E; Karakantza M; Pantazis P; Spyridonidis A; Zoumbos NC
Leukemia; 2008 Oct; 22(10):1899-908. PubMed ID: 18650843
[TBL] [Abstract][Full Text] [Related]
28. Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants.
Siehl JM; Reinwald M; Heufelder K; Menssen HD; Keilholz U; Thiel E
Ann Hematol; 2004 Dec; 83(12):745-50. PubMed ID: 15340762
[TBL] [Abstract][Full Text] [Related]
29. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
Fialin C; Larrue C; Vergez F; Sarry JE; Bertoli S; Mansat-De Mas V; Demur C; Delabesse E; Payrastre B; Manenti S; Roche S; Récher C
Leukemia; 2013 Feb; 27(2):325-35. PubMed ID: 22902361
[TBL] [Abstract][Full Text] [Related]
30. Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868.
Jordheim LP; Plesa A; Dreano M; Cros-Perrial E; Keime C; Herveau S; Demangel D; Vendrell JA; Dumontet C
Cancer Chemother Pharmacol; 2011 Jul; 68(1):97-105. PubMed ID: 20844879
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of in vivo cytarabine-induced gene expression signature in AML.
Lamba JK; Pounds S; Cao X; Crews KR; Cogle CR; Bhise N; Raimondi SC; Downing JR; Baker SD; Ribeiro RC; Rubnitz JE
Leuk Lymphoma; 2016; 57(4):909-20. PubMed ID: 26366682
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and Prognostic Impact of Wilms' Tumor 1 (WT1) Gene, Including SNP rs16754 in Cytogenetically Normal Acute Myeloblastic Leukemia (CN-AML): An Iranian Experience.
Toogeh G; Ramzi M; Faranoush M; Amirizadeh N; Haghpanah S; Moghadam M; Cohan N
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):e21-6. PubMed ID: 26725263
[TBL] [Abstract][Full Text] [Related]
33. Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs.
Lopotová T; Polák J; Schwarz J; Klamová H; Moravcová J
Blood Cells Mol Dis; 2012 Jun; 49(1):41-7. PubMed ID: 22555024
[TBL] [Abstract][Full Text] [Related]
34. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
35. FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3.
Damdinsuren A; Matsushita H; Ito M; Tanaka M; Jin G; Tsukamoto H; Asai S; Ando K; Miyachi H
Leuk Res; 2015 Dec; 39(12):1405-13. PubMed ID: 26475207
[TBL] [Abstract][Full Text] [Related]
36. Identification of a potential topoisomerase II "hotspot" DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms.
Piredda ML; Catalano G; Ciardi C; Divona M; Cicconi L; Panetta P; Curzi P; Garza E; Martínez-Losada C; Postorino M; Lo-Coco F; Noguera NI
Ann Hematol; 2017 Jan; 96(1):155-157. PubMed ID: 27734129
[No Abstract] [Full Text] [Related]
37. Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
Chiriches C; Khan D; Wieske M; Guillen N; Rokicki M; Guy C; Wilson M; Heesom KJ; Ottmann OG; Ruthardt M
Ann Hematol; 2022 Oct; 101(10):2179-2193. PubMed ID: 35941390
[TBL] [Abstract][Full Text] [Related]
38. Deregulation of mitochondrial ATPsyn-β in acute myeloid leukemia cells and with increased drug resistance.
Xiao X; Yang J; Li R; Liu S; Xu Y; Zheng W; Yi Y; Luo Y; Gong F; Peng H; Pei M; Deng M; Zhang G
PLoS One; 2013; 8(12):e83610. PubMed ID: 24391795
[TBL] [Abstract][Full Text] [Related]
39. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
[TBL] [Abstract][Full Text] [Related]
40. Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors.
Tatsumi N; Oji Y; Tsuji N; Tsuda A; Higashio M; Aoyagi S; Fukuda I; Ito K; Nakamura J; Takashima S; Kitamura Y; Miyai S; Jomgeow T; Li Z; Shirakata T; Nishida S; Tsuboi A; Oka Y; Sugiyama H
Int J Oncol; 2008 Mar; 32(3):701-11. PubMed ID: 18292948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
